National Breast Cancer Month Spotlights Awareness Efforts

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 12
Volume 4
Issue 12

WASHINGTON--Zeneca Pharmaceuticals and its National Breast Cancer Awareness Month (NBCAM) co-sponsors have presented First Lady Hillary Rodham Clinton with the Government Leadership Award for her outstanding initiative in launching efforts to educate women about mammography.

WASHINGTON--Zeneca Pharmaceuticals and its National Breast CancerAwareness Month (NBCAM) co-sponsors have presented First LadyHillary Rodham Clinton with the Government Leadership Award forher outstanding initiative in launching efforts to educate womenabout mammography.

Special awards were given to three sets of "partners"who have played pivotal roles in breast cancer awareness: formerFirst Lady Betty Ford and her daughter Susan Ford Bales; NancyBrinker and, posthumously, her sister, Susan G. Komen; and HarveyKushner and, posthumously, his wife, Rose.

Community outreach programs honored were Carilion Health System,Roanoke, Va; Emory University School of Medicine; and HartfordHospital.

Awards for achievement in providing employees access to breastcancer screening and education at the worksite went to MetrolinaOutreach Mammography, Charlotte, NC, and Tri Valley Growers, SanFrancisco.

In the print media category, Oncology Times received an awardfor its stories on the National Surgical Adjuvant Breast and BowelProject.

Primary Care & Cancer, under the editorial directionof James McCarthy and published by PRR, Inc. (which also publishesthe journal Oncology and Oncol-ogy News International), was honoredfor its Breast Self-Examination Guide, and John Gentile, Jr.,president of PRR, won an Awareness Achievement Award (see photographbelow), which he accepted on behalf of the entire staff.

Recent Videos
Regardless of disease burden or disease progression speed on front-line therapy, trastuzumab deruxtecan appears effective in HER2-low breast cancer.
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Related Content